Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ryuta Sobu"'
Autor:
Kazuyuki Numakura, Mizuki Kobayashi, Yumina Muto, Hiromi Sato, Yuya Sekine, Ryuta Sobu, Yu Aoyama, Yoshiko Takahashi, Syuhei Okada, Hajime Sasagawa, Shintaro Narita, Satoshi Kumagai, Yuki Wada, Naoko Mori, Tomonori Habuchi
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8092-8110 (2023)
A recent approach to radiotherapy for prostate cancer is the administration of high doses of radiation to the prostate while minimizing the risk of side effects. Thus, image-guided radiotherapy utilizes advanced imaging techniques and is a feasible s
Externí odkaz:
https://doaj.org/article/e0a1eacacfc045a19b1684955e5aae44
Autor:
Kazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, Yumina Muto, Ryuta Sobu, Mizuki Kobayashi, Hajime Sasagawa, Soki Kashima, Ryohei Yamamto, Taketoshi Nara, Hideo Akashi, Ryuji Tabata, Satoshi Sato, Mitsuru Saito, Shintaro Narita, Chikara Ohyama, Tomonori Habuchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 16837-16845 (2023)
Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) is the first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease
Externí odkaz:
https://doaj.org/article/071fb040d8e54cf6807375d01f877ff2
Autor:
Keisuke Okubo, Shintaro Narita, Atsushi Koizumi, Yoshiko Takahashi, Ryuichiro Sagehashi, Kanami Mori, Ryuta Sobu, Hiromi Sato, Soki Kashima, Mizuki Kobayashi, Ryohei Yamamoto, Taketoshi Nara, Kazuyuki Numakura, Mitsuru Saito, Hiroshi Nanjyo, Tomonori Habuchi
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 621-627 (2023)
A 66-year-old male was diagnosed with cT4N0M1b small-cell neuroendocrine carcinoma of the prostate. Four months after the administration of combined androgen blockade, multiple novel metastatic regions in the lung and liver and progression of bone me
Externí odkaz:
https://doaj.org/article/f2d15b40e88647d68f625a2c33fd5ce0
Autor:
Ryuta Sobu, Kazuyuki Numakura, Sei Naito, Shingo Hatakeyama, Renpei Kato, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Syuya Kandori, Sadafumi Kawamura, Yoichi Arai, Akihiro Ito, Hiroyuki Nishiyama, Yoshiyuki Kojima, Wataru Obara, Chikara Ohyama, Norihiko Tsuchiya, Tomonori Habuchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4100-4109 (2023)
Abstract It remains unknown whether the early response to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) management in malignancies links to long‐term survival. The objective of this study was to investigate the
Externí odkaz:
https://doaj.org/article/24099fdcb8384362b97b3056f59518f8
Autor:
Ryuta Sobu, Kazuyuki Numakura, Sei Naito, Shingo Hatakeyama, Renpei Kato, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Syuya Kandori, Sadafumi Kawamura, Yoichi Arai, Akihiro Ito, Hiroyuki Nishiyama, Yoshiyuki Kojima, Wataru Obara, Chikara Ohyama, Norihiko Tsuchiya, Tomonori Habuchi
Publikováno v:
Cancer medicineREFERENCES.
It remains unknown whether the early response to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) management in malignancies links to long-term survival. The objective of this study was to investigate the survival rat